Ustekinumab is a fully human monoclonal antibody directed against the p40 subunit shared by interleukin-12 and interleukin-23. The SHIKARI® Ustekinumab portfolio supports research into drug concentration, specific free-drug concentration, binding anti-drug antibodies and free neutralising antibodies across five distinct assay formats.
Ustekinumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Ustekinumab is a fully human IgG1κ monoclonal antibody that binds the shared p40 subunit of interleukin-12 and interleukin-23, inhibiting signalling from both cytokines. Source ↗
EMA-authorised uses include plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, with paediatric use in selected psoriasis and Crohn’s disease populations. EMA source ↗
FDA pharmacokinetic data for 90 mg subcutaneous maintenance every eight weeks provide indication-specific trough references:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Enzyme immunoassay for the quantitative determination of ustekinumab in human serum and plasma, developed for concentration measurement between the Cmin and Cmax range.
Enzyme immunoassay for the specific and quantitative determination of free ustekinumab in human serum and plasma, developed for concentration measurement between the Cmin and Cmax range.
Enzyme immunoassay for the quantitative determination of specific antibodies to ustekinumab in human serum and plasma, with confirmation.
Enzyme immunoassay for the qualitative determination of specific antibodies to ustekinumab in human serum and plasma. No standard curve is shown because this is a qualitative assay.
Qualitative enzyme immunoassay for detecting free neutralising antibodies to ustekinumab in human serum and plasma. Four control types are supplied, including a non-neutralising antibody negative control.
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-UST | UST-FD-STE | Drug-Level Kit | Ustekinumab | ELISA | 96 | 2–8°C |
| SHIKARI® QS-UST | UST-SPEC-UST | Specific Drug-Level Kit | Specific free ustekinumab | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATU with confirmation | UST-QNS-STE | Quantitative ADA Kit | Anti-ustekinumab antibodies | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATU qualitative | UST-QLS-STE | Qualitative ADA Kit | Anti-ustekinumab antibodies | ELISA | 96 | 2–8°C |
| SHIKARI® T-CAP NAb Assay™ | UST-TCAP-NAb-STE | Neutralising Antibody Kit | Free neutralising antibodies to ustekinumab | ELISA | 96 | 2–8°C |
* Store at +4°C and refer to the current protocol supplied with the kit. Specifications were verified against the official product records.
Choose the assay by analyte and measurement mode rather than treating drug concentration, binding antibodies and neutralising antibodies as equivalent.
Matrix Biotek can help identify the appropriate Ustekinumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.